Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Horm Res Paediatr. 2012;77(3):188-94. doi: 10.1159/000337570. Epub 2012 Apr 12.
Gender may affect growth hormone (GH) treatment outcome. This study assessed gender-related differences in change from baseline height standard deviation scores (ΔHSDS) after 2 years' GH treatment.
Data from two observational databases were analyzed - the NordiNet® International Outcome Study (NordiNet® IOS) and the American Norditropin Studies: Web Enabled Research Program (ANSWER Program®). Of all the evaluated patients (n = 5,880; age 0 to <18 years), 4,471 were diagnosed with GH deficiency (GHD), 422 with multiple pituitary hormone deficiency, and 987 were born small for gestational age (SGA). Data were analyzed by indication, gender and pubertal status (total population/prepubertal).
In the total population, after correcting for dose, mean baseline age and HSDS, ΔHSDS was significantly greater in boys than in girls born SGA (p = 0.0261). In the prepubertal cohort, ΔHSDS was significantly greater for boys versus girls with GHD (p = 0.0004) and SGA (p = 0.0019). No between-gender difference in ΔIGF-I SDS was found.
A significant gender difference was found in the 2-year response to GH treatment in the total population of SGA children as well as in the prepubertal cohorts of SGA and GHD children.
性别可能会影响生长激素（GH）治疗的结果。本研究评估了接受 2 年 GH 治疗后，身高标准差评分（ΔHSDS）从基线变化的性别差异。
分析了来自两个观察性数据库的数据——NordiNet®国际结果研究（NordiNet®IOS）和美国诺和诺德生长激素研究：网络增强研究计划（ANSWER 计划®）。在所评估的所有患者（n=5880；年龄 0 至<18 岁）中，4471 例诊断为生长激素缺乏症（GHD），422 例为多种垂体激素缺乏症，987 例为小于胎龄儿（SGA）。数据分析按适应症、性别和青春期状态（总体人群/青春期前）进行。
在总体人群中，在校正剂量、平均基线年龄和 HSDS 后，SGA 出生的男孩与女孩相比，ΔHSDS 显著更大（p=0.0261）。在青春期前队列中，与 GHD（p=0.0004）和 SGA（p=0.0019）的女孩相比，男孩的ΔHSDS 显著更大。未发现 IGF-I SDS 的性别差异。
在 SGA 儿童的总体人群以及 SGA 和 GHD 儿童的青春期前队列中，GH 治疗 2 年后的反应存在显著的性别差异。
